Glaukos (NYSE:GKOS) Given New $160.00 Price Target at Stifel Nicolaus

Glaukos (NYSE:GKOS) had its target price lifted by Stifel Nicolaus from $115.00 to $160.00 in a research note issued to investors on Thursday, MarketBeat.com reports. The firm currently has a buy rating on the medical instruments supplier’s stock.

Several other research analysts also recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Glaukos in a research note on Wednesday, October 8th. Wells Fargo & Company raised their target price on Glaukos from $120.00 to $122.00 and gave the stock an “overweight” rating in a research note on Thursday, October 30th. Citigroup upped their price objective on shares of Glaukos from $113.00 to $125.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. Truist Financial lifted their target price on shares of Glaukos from $120.00 to $145.00 and gave the company a “buy” rating in a report on Thursday, December 18th. Finally, Piper Sandler reissued an “overweight” rating and issued a $165.00 target price on shares of Glaukos in a research report on Wednesday, January 14th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $131.38.

Glaukos Trading Up 1.5%

NYSE GKOS opened at $125.98 on Thursday. Glaukos has a 1 year low of $73.16 and a 1 year high of $163.71. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.20 and a quick ratio of 4.47. The company has a market capitalization of $7.24 billion, a PE ratio of -81.81 and a beta of 0.67. The company has a fifty day moving average of $109.93 and a 200 day moving average of $96.15.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Wednesday, October 29th. The medical instruments supplier reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.11. Glaukos had a negative net margin of 18.65% and a negative return on equity of 7.52%. The business had revenue of $133.54 million for the quarter, compared to analysts’ expectations of $122.55 million. During the same quarter last year, the company earned ($0.28) EPS. The business’s revenue was up 38.1% on a year-over-year basis. Research analysts forecast that Glaukos will post -1.08 earnings per share for the current year.

Insider Activity at Glaukos

In other Glaukos news, CEO Thomas William Burns sold 186,945 shares of the firm’s stock in a transaction on Friday, January 16th. The shares were sold at an average price of $115.00, for a total transaction of $21,498,675.00. Following the transaction, the chief executive officer directly owned 153,775 shares of the company’s stock, valued at approximately $17,684,125. This trade represents a 54.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Joseph E. Gilliam sold 19,340 shares of the firm’s stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $90.00, for a total value of $1,740,600.00. Following the transaction, the chief operating officer directly owned 92,366 shares in the company, valued at approximately $8,312,940. This represents a 17.31% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 299,655 shares of company stock worth $33,935,025. Insiders own 5.80% of the company’s stock.

Institutional Investors Weigh In On Glaukos

A number of institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC increased its holdings in Glaukos by 2.6% in the first quarter. AQR Capital Management LLC now owns 7,788 shares of the medical instruments supplier’s stock valued at $766,000 after buying an additional 198 shares in the last quarter. Jones Financial Companies Lllp grew its holdings in shares of Glaukos by 1,405.9% in the 1st quarter. Jones Financial Companies Lllp now owns 2,560 shares of the medical instruments supplier’s stock worth $252,000 after acquiring an additional 2,390 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Glaukos by 41.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 229,994 shares of the medical instruments supplier’s stock valued at $22,636,000 after purchasing an additional 67,668 shares in the last quarter. Assenagon Asset Management S.A. purchased a new position in Glaukos in the 2nd quarter valued at approximately $1,245,000. Finally, GAMMA Investing LLC raised its holdings in Glaukos by 56.0% during the second quarter. GAMMA Investing LLC now owns 2,109 shares of the medical instruments supplier’s stock worth $218,000 after purchasing an additional 757 shares during the last quarter. Hedge funds and other institutional investors own 99.04% of the company’s stock.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.